Bolak Company Limited Overview
Bolak is one of Korea's longest-established specialty ingredient manufacturers. It has been listed on the KOSPI for decades and operates from a single integrated site in Hwaseong, Gyeonggi Province. The company supplies flavours, food colours, chewing-gum base, and functional food additives to Korean confectionery, beverage, dairy, and consumer-goods producers. It also manufactures pharmaceutical raw materials, notably herbal-extract APIs, natural paclitaxel, docetaxel trihydrate, and cellulose-based excipients (Na-CMC and Ca-CMC), along with cosmetic ingredients and fragrances. With FY2025 revenue of KRW 50.1bn and about 140 staff, Bolak is a micro-cap and a price-taker relative to global flavour houses. Its edge is breadth of portfolio, long-standing domestic customer relationships, a debt-light balance sheet (net cash of KRW 6.8bn at FY2025), and a regulated API capability that most domestic food-additive peers lack. Margins are thin and volatile (operating margin between −3.8% and 6.8% over FY2021–FY2025). The equity is heavily influenced by the controlling family's widely reported connection to the LG Group chairman's household. [S1, S2, S3, S10, S11]
What the company does
Bolak develops, manufactures, and sells ingredients for four broad customer universes:
-
Food and beverage manufacturers. Products include flavours for confectionery, beverages, dairy, seasonings, and "micron" flavour formats; food colours (natural extracts, synthetic, and blended synthetic); chewing-gum base; and a wide range of additives including sweeteners, surfactants, preservatives, antioxidants, thickeners, caffeine, and baking powder. [S2, S8, S16]
-
Pharmaceutical manufacturers. Products include herbal-extract APIs (dry and soft extract powders, fluid extracts, tinctures), the oncology APIs natural paclitaxel and docetaxel trihydrate, and the cellulose derivatives Na-CMC and Ca-CMC used as excipients. [S2, S16]
-
Health functional food producers. Products include green tea extracts, soy isoflavones, and ginseng extracts. [S2, S7]
-
Cosmetics, personal care, and household-goods makers. Products include cosmetic ingredients and fragrances for perfumes, cosmetics, hair products, daily-use goods, toilet soaps, candles, and industrial products, plus whitening agents and abrasives. Legacy profiles also cite flavours for toothpaste and tobacco, and production of chocolate and Ca-CMC. [S2, S18, S21]
The company's own description
Bolak's English-language annual report is not published, and the DART business report narrative could not be accessed directly. Data providers that summarise the DART filing consistently describe the company as manufacturing and selling food ingredients, pharmaceutical raw materials, functional materials, and cosmetic ingredients in Korea and internationally. [S2, S7] Morningstar characterises it more narrowly as a manufacturer of food additives and active pharmaceutical ingredients. [S6] The verbatim "business overview" chapter of the FY2025 business report is not publicly disclosed in accessible sources.
Business and revenue model
| Dimension | Characterisation |
|---|---|
| Revenue model | Almost entirely product sales (B2B ingredient manufacturing). No subscription, licensing, or service revenue is disclosed. A small fee-income line of about KRW 0.17–0.22bn per year appears in non-operating income [S5]. |
| Value-chain position | Mid-stream. Bolak converts commodity and botanical inputs (raw materials were KRW 27.8bn, about 66% of FY2025 cost of sales [S5]) into formulated ingredients sold to branded consumer-goods and pharmaceutical companies. It does not sell to consumers [S3]. |
| Customer types | Korean confectionery, beverage, dairy, and bakery producers; gum manufacturers; generic and herbal pharmaceutical companies; health functional food producers; cosmetics and household-goods companies. Named customers are not publicly disclosed, apart from media allegations of material sales to LG Household & Health Care (see Section 19) [S10]. |
| End markets | Packaged food and confectionery, beverages, dairy, pharmaceuticals (herbal medicines, oncology generics, excipients), nutraceuticals, cosmetics and personal care. |
| Mix (Q2 FY2026) | Food additives 56%, other 24%, APIs 20% of quarterly revenue [S4]. |
| Geography | Overwhelmingly domestic. Aggregator data imply LTM export revenue of only KRW 0.8–2.3bn (about 2–5% of sales) over Jun 2025 – Jun 2026 [S5]. See Section 7 for caveats. |
Independent characterisation
Bolak is best understood as a diversified domestic ingredient workshop with an embedded API niche. It is not a scaled flavour house. Annual revenue of about KRW 50bn is roughly one-hundredth of Symrise's or Givaudan's flavour-and-fragrance sales [S19, S20]. Gross margins of 9–17% over FY2021–FY2025 [S2] are characteristic of commodity-blending and contract manufacturing, not proprietary formulation. Global leaders, by contrast, run gross margins above 40% (Givaudan reported 43.5% for 2025 [S19]).
Three features distinguish Bolak from a pure commodity blender:
Regulated pharmaceutical manufacturing: It produces natural paclitaxel and docetaxel trihydrate. This places it in a niche oncology API market that one industry study sizes at roughly USD 200M globally by 2030 [S14].
Gum base capability: Gum base is a technically specific, consolidated product category with few domestic producers [S8].
Large, conservatively financed asset base: Total assets are KRW 59.2bn, including land carried at KRW 19.1bn [S2]. Book value per share is KRW 814 [S2], close to the share price.
Strategy
Stated strategy. Bolak publishes no investor-day materials, mid-term plan, or English-language strategy statement. The strategy and outlook narrative in the FY2025 DART business report was not accessible, so verbatim strategic themes are not publicly disclosed in accessible sources.
Initiatives observable from filings and financials (last 24 months):
Not publicly disclosed: sustainability or ESG commitments, cost programmes with quantified targets, new business launches, partnerships, and medium-term financial targets or guidance.
Products & Services
Product-level specifications, launch years, pricing models, and named flagship brands are not publicly disclosed in accessible sources. The company sells under its corporate name to B2B customers, and the website catalogue could not be retrieved. The catalogue below is the most granular publicly documented list, organised by revenue bucket.
Food additives (56% of Q2 FY2026 revenue)
| Product line | Description and known capabilities | Target customer | Source |
|---|---|---|---|
| Confectionery flavours | Flavours for candy, gum, chocolate, ice cream, and frozen confections | Confectionery and ice-cream makers | S2, S21 |
| Beverage flavours | Flavours for soft drinks and other beverages | Beverage bottlers and brand owners | S2, S21 |
| Dairy flavours | Flavours for dairy products | Dairy processors | S2, S8 |
| "Micron" flavours | Listed as a distinct flavour format; likely a fine-particle or encapsulated powder flavour (characterisation not company-confirmed) | Dry-mix, powder, and confectionery applications | S2 |
| Seasoning flavours and herbal essences | Savoury seasoning flavours; herbal essences | Processed-food and seasoning makers | S8 |
| Oral-care and tobacco flavours | Flavours used in toothpaste and tobacco | Oral-care and tobacco manufacturers | S18, S21 |
| Food colours, natural | Naturally extracted colouring agents | Food and beverage makers | S2, S8 |
| Food colours, synthetic and blended | Synthetic and mixed synthetic colouring agents | Food, confectionery, and pharma coating users | S8 |
| Chewing-gum base | Gum base for stick, tablet, coated, powder-pressed, centre-filled, and sugar-free gum | Gum manufacturers | S8 |
| Sweeteners | Sweetening agents | Food and beverage makers | S2 |
| Preservatives and antioxidants | Shelf-life and oxidation-control additives | Food processors | S2, S3 |
| Thickeners and thickening agents | Texture and viscosity modifiers (including CMC grades) | Food processors | S2 |
| Surfactants and emulsifiers | Surface-active agents | Food and cosmetics processors | S2 |
| Caffeine | Caffeine ingredient | Beverage and pharma customers | S2 |
| Baking powder | Leavening agent | Bakery and industrial food producers | S2 |
| Chocolate | Listed in legacy profiles as a product | Confectionery customers | S18, S21 |
Active pharmaceutical ingredients (20% of Q2 FY2026 revenue)
| Product line | Description and known capabilities | Target customer | Source |
|---|---|---|---|
| Dry extract powders | Standardised herbal extract APIs in powder form | Herbal and ethical pharmaceutical companies | S2, S8 |
| Soft (viscous) extracts | Concentrated viscous herbal extracts | Herbal medicine manufacturers | S2, S8 |
| Fluid extracts | Liquid botanical extracts | Pharmaceutical manufacturers | S2, S8 |
| Tinctures | Alcoholic botanical extracts | Pharmaceutical manufacturers | S2, S8 |
| Natural paclitaxel | Taxane cytotoxic oncology API derived from yew biomass (natural route) | Oncology generic and injectable formulators | S2, S16 |
| Docetaxel trihydrate | Semi-synthetic taxane oncology API | Oncology generic formulators | S2, S16 |
| Na-CMC (sodium carboxymethylcellulose) | Cellulose ether excipient (binder, thickener) | Pharma and food | S2, S16 |
| Ca-CMC (calcium carboxymethylcellulose) | Cellulose ether excipient (disintegrant) | Pharma tablet manufacturers | S2, S18 |
Paclitaxel IP. In October 2024, media reported that Bolak holds a patent on a drug-delivery system for paclitaxel relevant to Daehwa Pharmaceutical's oral formulation Liporaxel. Daehwa developed Liporaxel on its DHLASED lipid-based self-emulsifying delivery platform. [S12] The commercial terms (licence, royalty, supply) linking Bolak to Liporaxel are not publicly disclosed. A securities-industry source quoted at the time flagged uncertainty over any earnings contribution. [S12]
Health functional food materials (reported within "Other" or food; classification not confirmed)
| Product line | Description | Target customer | Source |
|---|---|---|---|
| Green tea extracts | Botanical extract for functional foods | Health functional food brands | S2 |
| Soy isoflavones | Phyto-oestrogen extract | Nutraceutical brands | S2 |
| Ginseng extracts | Korean ginseng extract materials | Health functional food and herbal brands | S2 |
Cosmetic ingredients and fragrances (within "Other")
| Product line | Description | Target customer | Source |
|---|---|---|---|
| Fine and functional fragrances | Fragrances for perfumes, cosmetics, hair products, daily-use goods, toilet soaps, candles, and industrial products | Cosmetics, personal-care, and household-goods makers | S2 |
| Cosmetic ingredients | Including whitening agents and abrasives | Cosmetics manufacturers | S2 |
| Industrial odorants and medical fragrances | Odorants for industrial use; fragrances for medical products | Industrial and medical-device customers | S8 |
Financial Narrative
All figures are from separate financial statements under K-IFRS. Primary dataset: S&P Global Market Intelligence via StockAnalysis.com [S2], cross-checked against DART-based ETF쇼핑 data [S3]. The two agree to within rounding on revenue, operating income, and net income. Gross-profit and R&D classifications differ slightly between providers: S&P shows FY2025 gross profit of KRW 7.83bn versus KRW 7.9bn on ETF쇼핑.
Income statement: notes and sources
Source: S2 (FY2021–FY2025). ValueLine's DART-based EBITDA for FY2025 is KRW 4.11bn [S5], versus KRW 3.93bn on S&P's definition.
Per-share data (KRW)
Source: S2 (EPS, BVPS, FCF/share); S3 (DPS, by fiscal year of record date). No dilutive instruments are reported.
Margins and growth (%)
Source: S2; R&D intensity computed. Revenue CAGR FY2021–FY2025 = 5.96% (computed from S2). Revenue CAGR FY2016–FY2025 = 3.84% (computed from S3).
Ten-year context: notes and sources
Source: S3 (DART business reports, FY2016–FY2025): ### Balance sheet: notes and sources
Source: S2. Short- and long-term debt splits computed from S2 line items. Goodwill is nil; intangibles are "other intangible assets" only. Land is carried at KRW 19.08bn in every year from FY2021 to FY2025 [S2].
Cash flow: notes and sources
Source: S2. Buybacks are nil in FY2021–FY2025. A KRW 1.5bn trust was contracted in Jul 2026 [S3].
Ratios
Source: computed from S2 data. ROIC uses a notional 20% tax rate because Bolak's effective tax rate swings widely (5.1% in FY2025; negative in FY2023–FY2024). S&P's own TTM figures to Jun 2026 are ROE 5.19% and ROIC 4.46% [S2].
Net debt / EBITDA. FY2021: 0.38x. FY2022: 0.01x. FY2023 and FY2025: net cash (−0.48x and −1.74x). FY2024: not meaningful, because EBITDA was negative (−KRW 26M) while the company held net cash. [S2; computed]
Latest interim position (LTM to 30 June 2026)
Source: S2: Q2 FY2026 preliminary results (29 Jul 2026) were revenue KRW 12.5bn, operating profit KRW 0.7bn, and net income KRW 0.9bn [S3]. Investing.com reports Q1 FY2026 revenue of KRW 11.21bn and EPS of KRW 9.06 [S15]. H1 FY2026 revenue was therefore about KRW 23.7bn. The fall in LTM revenue from KRW 50.1bn to KRW 47.0bn implies H1 FY2026 revenue was roughly 11–12% below H1 FY2025 (computed). At 30 Jun 2026, cash was KRW 7.47bn, debt KRW 1.06bn, net cash KRW 6.41bn, and equity KRW 49.68bn (book value per share KRW 829.47) [S2].
Commentary on trends, inflections, and drivers
Revenue. Bolak's top line was essentially stagnant for most of the decade (KRW 33.5–38.3bn in FY2017–FY2020 [S3]). It then stepped up in FY2022, when revenue grew 21.8% to KRW 48.4bn [S2]. The step-up coincided with the 2022 global food-inflation cycle, and inventory build in FY2022 (KRW 3.3bn cash outflow) suggests price pass-through on higher input costs rather than purely volume-driven growth [S2]. Revenue then plateaued at KRW 47–50bn. FY2025 reached a 10-year high of KRW 50.1bn, but the LTM figure has since slipped to KRW 47.0bn. Export revenue in particular appears to have declined. The absence of a disclosed segment history prevents attribution between food additives and APIs.
Gross margin is the swing factor. Gross margin collapsed from 17.0% in FY2022 to 9.0% in FY2024, then recovered to 15.6% in FY2025 and 17.2% LTM [S2]. Two observations point to cost-side and inventory-valuation effects, not price competition alone:
-
ValueLine's cost breakdown shows raw-material cost broadly flat at KRW 27–30bn, while "other" cost-of-sales items swung sharply between periods [S5].
-
FY2024 carried an unusual KRW 0.98bn "other operating expense" [S2].
The nature of the FY2024 charge (possible inventory write-down or impairment) is not publicly disclosed in accessible sources. The record inventory of KRW 16.9bn at FY2024 year-end, followed by a KRW 4.0bn reduction in FY2025, is consistent with a destocking and write-down cycle [S2].
Operating leverage is high relative to scale. SG&A plus R&D runs at about KRW 5.3–5.6bn per year [S2]. Each percentage point of gross margin is worth about KRW 0.5bn, a quarter of FY2025 operating profit. Labour is a large fixed cost: payroll was KRW 8.43bn in FY2025, 16.8% of revenue [S1].
Cash generation inflected in FY2025. Operating cash flow reached KRW 7.17bn, about 3x net income, driven by the KRW 3.5bn inventory release [S2]. This funded KRW 1.09bn of debt repayment and lifted cash to KRW 7.9bn. The LTM figure to June 2026 (OCF KRW 4.6bn, FCF KRW 3.2bn) shows the working-capital tailwind fading [S2]. Underlying cash earnings (net income plus D&A) are about KRW 4bn per year.
Balance sheet. The balance sheet is very conservative. Equity of KRW 48.7bn funds 82% of assets. Debt fell to KRW 1.1bn at FY2025 [S2], of which KRW 1.03bn is current and due in 2026. The asset base is dominated by property, plant and equipment (KRW 26.4bn, including land at historical cost of KRW 19.1bn) and inventory [S2]. Return on capital is structurally low (ROE 4.8% in FY2025) because a large equity base supports a thin-margin business.
Capital intensity is low. Capex averaged KRW 0.68bn per year over FY2021–FY2025, against D&A of about KRW 1.9bn [S2]. The asset base is therefore being depreciated faster than it is renewed. FY2025 capex of KRW 1.26bn is the highest in the period.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment (Q2 FY2026) Overview
| Segment (Q2 FY2026) | Share of revenue (%) | Implied revenue (KRW Mn) |
|---|---|---|
Food additives | 56 | 7,000 |
Other (incl. cosmetic ingredients, fragrances, functional materials, merchandise) | 24 | 3,000 |
Active pharmaceutical ingredients | 20 | 2,500 |
Total | 100 | 12,500 |
Income Statement
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (KRW Mn) | 39,764 | 48,435 | 46,774 | 47,600 | 50,116 |
Cost of revenue (KRW Mn) | 33,315 | 40,209 | 41,135 | 43,304 | 42,282 |
Gross profit (KRW Mn) | 6,449 | 8,225 | 5,639 | 4,296 | 7,834 |
SG&A (KRW Mn) | 3,431 | 3,656 | 3,743 | 4,057 | 4,551 |
R&D expense (KRW Mn) | 1,137 | 1,071 | 990 | 870 | 796 |
Operating income (KRW Mn) | 1,692 | 3,283 | 506 | -1,792 | 2,230 |
D&A (KRW Mn) | 2,040 | 1,982 | 1,891 | 1,766 | 1,704 |
EBITDA (KRW Mn) | 3,732 | 5,265 | 2,396 | -26 | 3,934 |
Interest expense (KRW Mn) | 75 | 68 | 90 | 97 | 66 |
Pre-tax income (KRW Mn) | 1,841 | 3,389 | 724 | -1,553 | 2,465 |
Income tax (KRW Mn) | 146 | 320 | -134 | -44 | 126 |
Net income (KRW Mn) | 1,695 | 3,069 | 858 | -1,510 | 2,340 |
Per-Share Data
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
EPS basic (KRW) | 28.30 | 51.24 | 14.32 | -25.20 | 39.06 |
EPS diluted (KRW) | 28.30 | 51.24 | 14.32 | -25.20 | 39.06 |
Dividend per share (KRW) | 5 | 7 | 5 | 5 | 7 |
Book value per share (KRW) | 760.33 | 807.74 | 814.34 | 778.81 | 813.53 |
Free cash flow per share (KRW) | 9.16 | 31.70 | 15.92 | 10.62 | 98.60 |
Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue growth YoY (%) | 3.84 | 21.81 | -3.43 | 1.77 | 5.29 |
Gross margin (%) | 16.22 | 16.98 | 12.05 | 9.03 | 15.63 |
Operating margin (%) | 4.25 | 6.78 | 1.08 | -3.76 | 4.45 |
EBITDA margin (%) | 9.39 | 10.87 | 5.12 | -0.06 | 7.85 |
Net margin (%) | 4.26 | 6.34 | 1.83 | -3.17 | 4.67 |
R&D / revenue (%) | 2.86 | 2.21 | 2.12 | 1.83 | 1.59 |
Income Statement and Margin Analysis (%)
| Metric | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenue (KRW Bn) | 35.7 | 33.5 | 33.8 | 36.1 | 38.3 | 39.8 | 48.4 | 46.8 | 47.6 | 50.1 |
Operating profit (KRW Bn) | 2.0 | 1.3 | 1.3 | 0.6 | 0.1 | 1.7 | 3.3 | 0.5 | -1.8 | 2.2 |
Net income (KRW Bn) | 3.0 | 1.2 | 1.1 | 0.6 | 0.4 | 1.7 | 3.1 | 0.9 | -1.5 | 2.3 |
Gross margin (%) | 16.4 | 16.3 | 16.2 | 13.6 | 12.4 | 16.4 | 17.2 | 12.2 | 9.2 | 15.7 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansBalance Sheet
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Total assets (KRW Mn) | 56,318 | 60,912 | 57,928 | 59,282 | 59,241 |
Cash and equivalents (KRW Mn) | 1,912 | 3,162 | 3,295 | 3,627 | 7,940 |
Receivables (KRW Mn) | 6,174 | 7,892 | 6,768 | 6,362 | 6,455 |
Inventory (KRW Mn) | 11,238 | 14,210 | 14,670 | 16,896 | 12,865 |
Total current assets (KRW Mn) | 20,693 | 26,264 | 25,120 | 27,854 | 27,966 |
Property, plant and equipment (KRW Mn) | 30,595 | 29,343 | 28,026 | 26,677 | 26,373 |
Goodwill and intangibles (KRW Mn) | 317 | 257 | 197 | 137 | 112 |
Short-term debt incl. current LTD and leases (KRW Mn) | 84 | 3,079 | 80 | 36 | 1,095 |
Long-term debt incl. leases (KRW Mn) | 3,232 | 153 | 2,073 | 2,041 | 9 |
Total debt (KRW Mn) | 3,315 | 3,232 | 2,153 | 2,077 | 1,104 |
Net debt (KRW Mn; negative = net cash) | 1,403 | 70 | -1,143 | -1,550 | -6,835 |
Total current liabilities (KRW Mn) | 4,842 | 9,810 | 4,659 | 5,931 | 7,973 |
Total liabilities (KRW Mn) | 10,774 | 12,529 | 9,149 | 12,631 | 10,511 |
Shareholders' equity (KRW Mn) | 45,544 | 48,384 | 48,779 | 46,651 | 48,731 |
Working capital (KRW Mn) | 15,851 | 16,455 | 20,462 | 21,923 | 19,992 |
Cash Flow
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Operating cash flow (KRW Mn) | 1,178 | 2,548 | 1,523 | 904 | 7,166 |
Capital expenditure (KRW Mn) | -629 | -650 | -569 | -268 | -1,260 |
Free cash flow (KRW Mn) | 549 | 1,899 | 954 | 636 | 5,906 |
Change in inventory (KRW Mn) | -1,726 | -3,312 | -552 | -2,906 | 3,534 |
Dividends paid (KRW Mn) | -240 | -300 | -419 | -300 | -300 |
Share buybacks (KRW Mn) | 0 | 0 | 0 | 0 | 0 |
Net debt issued / repaid (KRW Mn) | -132 | -84 | -1,079 | -89 | -1,094 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
ROE, year-end equity (%) | 3.72 | 6.34 | 1.76 | -3.24 | 4.80 |
ROA, year-end assets (%) | 3.01 | 5.04 | 1.48 | -2.55 | 3.95 |
ROIC, EBIT x (1-20%) / (equity + debt - cash) (%) | 2.88 | 5.42 | 0.85 | -3.18 | 4.26 |
Current ratio (x) | 4.27 | 2.68 | 5.39 | 4.70 | 3.51 |
Debt / equity (x) | 0.073 | 0.067 | 0.044 | 0.045 | 0.023 |
Interest coverage, EBIT / interest (x) | 22.5 | 48.6 | 5.6 | -18.4 | 33.6 |
Asset turnover, revenue / year-end assets (x) | 0.71 | 0.80 | 0.81 | 0.80 | 0.85 |
Days sales outstanding (days) | 56.2 | 58.8 | 52.2 | 44.7 | 44.0 |
Days inventory outstanding (days) | 123.1 | 129.0 | 130.2 | 142.4 | 111.1 |
Days payables outstanding (days) | 16.1 | 28.9 | 11.2 | 15.2 | 13.0 |
Cash conversion cycle (days) | 163.2 | 158.9 | 171.2 | 171.9 | 142.1 |
Income Statement (FY2025–LTM Jun-2026)
| Metric | FY2025 | LTM Jun-2026 |
|---|---|---|
Revenue (KRW Mn) | 50,116 | 47,032 |
Gross profit (KRW Mn) | 7,834 | 8,086 |
Operating income (KRW Mn) | 2,230 | 2,275 |
Net income (KRW Mn) | 2,340 | 2,524 |
EBITDA (KRW Mn) | 3,934 | 3,963 |
Operating cash flow (KRW Mn) | 7,166 | 4,568 |
Free cash flow (KRW Mn) | 5,906 | 3,231 |
Revenue by Region and Revenue by Region (%)
| Metric | LTM Jun-2025 | LTM Sep-2025 | LTM Dec-2025 | LTM Mar-2026 | LTM Jun-2026 |
|---|---|---|---|---|---|
Export revenue (KRW Mn) | 1,780 | 2,280 | 1,810 | 1,370 | 790 |
Total revenue (KRW Mn) | 51,180 | 50,490 | 50,110 | 48,270 | 47,030 |
Export share (%) | 3.5 | 4.5 | 3.6 | 2.8 | 1.7 |
Valuation Snapshot
| Metric | Value | Source |
|---|---|---|
Last close (15 Oct 2026) | KRW 931 | S3 |
1-month return | -6.5% | S3 |
6-month return | -21.5% | S3 |
1-year return | -9.8% | S3 |
52-week range | KRW 837–1,323 (ETF쇼핑, to 15 Oct 2026). Investing.com shows KRW 814–1,527 (as of Aug 2026) over a different look-back window. | S3, S15 |
Beta (5-year) | 0.31 (S&P) / 0.387 (StockHub) | S2, S16 |
Average daily volume | About 56,000 shares (20-day, Sep 2026). Investing.com shows a 3-month average of about 300,000, which reflects event spikes. | S2, S15 |
Share Price
| Metric | Q2 FY2025 | Q3 FY2025 | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 |
|---|---|---|---|---|---|
Quarter-end share price (KRW) | 1,023 | 1,039 | 1,047 | 1,148 | 838 |
Valuation Multiples
| Multiple | Bolak | Basis | Source |
|---|---|---|---|
P/E (trailing) | 22.1x | LTM EPS KRW 42.13 | S2; computed |
P/E (FY2025) | 23.8x | FY2025 EPS KRW 39.06 | S2, S3 |
EV/EBITDA (trailing) | 12.5x | EV about KRW 49.4bn ÷ LTM EBITDA KRW 3.96bn | Computed from S2, S3 |
EV/Sales (trailing) | 1.05x | EV ÷ LTM revenue KRW 47.03bn | Computed |
P/B | 1.12x | BVPS KRW 829.47 (Jun 2026) | S2; computed |
P/FCF | About 17x | LTM FCF KRW 3.23bn | Computed from S2 |
Dividend yield | 0.75% | FY2025 DPS KRW 7 | Computed from S3 |
Altman Z-score / Piotroski F-score | 6.39 / 6 | S&P, Sep 2026 | S2 |
Per-Share Data and Returns & Leverage Ratios (%)
| Metric | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
DPS, split-adjusted (KRW) | 14 | 7 | 5 | 5 | 4 | 5 | 7 | 5 | 5 | 7 |
Payout ratio (%) | 34 | 27 | 46 | 61 | 18 | 14 | 35 | 0 | 18 | 18 |
Capital Markets
| Item | Detail | Source |
|---|---|---|
Authorisation | KRW 1.5bn treasury-share acquisition trust (board resolution, 6 Jul 2026) | S3 |
Implied size | About 1.5–1.6 million shares at KRW 931–1,000 (about 2.6% of shares outstanding; computed) | Computed |
Execution | Daily trust purchases of about 10,000–20,000 shares observed Aug–Oct 2026; status report filed 6 Oct 2026 | S4 |
Prior buybacks | None in FY2016–FY2025 | S2, S3 |
Credit ratings (Moody's / S&P / Fitch) | Not rated; no public bonds | — |
Debt maturity profile | FY2025: KRW 1,032M current portion of long-term debt (due within 2026); KRW 8.1M long-term debt; leases of KRW 64M | S2 |
Mar 2026 | Current portion of long-term debt still KRW 1,032M; total debt KRW 1.08bn | S2 |
Interest expense | KRW 66M (FY2025); interest coverage about 34x | S2 |
Analyst Conclusions
Guidance and consensus
Management guidance: not publicly disclosed. Bolak issues no forward guidance.
Consensus: not available, as there is no sell-side coverage [S16].
Implied run-rate. H1 FY2026 revenue was about KRW 23.7bn [S3, S15]. Q2 FY2026 operating profit was KRW 0.7bn [S3], and LTM operating profit was KRW 2.28bn [S2]. On these figures, FY2026 revenue would land at about KRW 47–49bn with operating profit of about KRW 2–2.5bn, assuming H2 is similar to H2 FY2025. This is an analyst extrapolation, not a forecast from the company.
Bull case
-
Margin normalisation is sustainable. Gross margin recovered from 9.0% (FY2024) to 17.2% LTM [S2]. If inventory discipline holds (DIO fell from 142 to 111 days [computed from S2]), operating margins of 5–6% are achievable. That would deliver operating profit of KRW 2.5–3.0bn on flat revenue.
-
Balance-sheet optionality. Net cash of KRW 6.4bn (Jun 2026) [S2], land carried at KRW 19.1bn [S2], and a P/B of 1.12x mean the downside is cushioned by tangible assets. The first-ever KRW 1.5bn buyback [S3] signals a shift toward capital returns that could expand under Korea's "Value-up" pressure.
-
API and paclitaxel optionality. A reported Liporaxel-linked delivery patent [S12] and a natural-paclitaxel API market growing at an estimated 7.7% CAGR [S14] provide upside not reflected in a company with only 20% API revenue [S4].
Bear case
-
Value-destructive returns. ROIC of about 4.5% sits below S&P's WACC estimate of 5.9% [S2]. Bolak earned less than KRW 2.5bn per year on KRW 49bn of equity in four of the last five years [S2].
-
Top-line erosion. LTM revenue fell 8.1% to KRW 47.0bn by June 2026 [S2], and exports collapsed to about KRW 0.8bn LTM [S5]. R&D cuts (−30% over 4 years [S2]) limit Bolak's ability to win new briefs.
-
Governance and disclosure discount. The controlling family holds 33.5% (39.8% including the second holder) [S2, S3]. Disclosure is minimal and there is no coverage [S16]. The stock trades on LG-family and drug-approval headlines [S11, S12] rather than fundamentals, so a re-rating requires governance change that is not in evidence.
Catalysts and monitorables (next 12 months)
| Catalyst / monitorable | Expected timing | What to watch |
|---|---|---|
| Q3 FY2026 results | ~6 Nov 2026 (estimated) [S2] | Revenue trend versus Q3 FY2025; gross margin at or above 16%; export recovery |
| Buyback completion and cancellation decision | Trust period (end date not disclosed) | Whether repurchased shares are cancelled or held |
| FY2026 dividend decision | ~Feb 2027 | DPS at or above KRW 7; payout rising above 20% |
| FY2026 business report | ~Mar 2027 | Segment revenue and profit disclosure; customer concentration; nature of FY2024 charges |
| Debt repayment | Through 2026 | KRW 1.03bn current portion of long-term debt [S2]; would make the company effectively debt-free |
| Liporaxel / paclitaxel commercial linkage | Any time | Disclosure of supply or royalty agreements |
| Controlling-shareholder activity | Ongoing | Further insider purchases (stake trended from 33.31% to 33.53%) [S3] |
| Input costs | Ongoing | Botanicals, sugar and sweetener prices; won exchange rate |
Analyst verdict
Bolak is a well-capitalised, low-return, domestically focused ingredient manufacturer whose equity story is driven more by its balance sheet and corporate-control context than by operating momentum.
The FY2025 recovery was genuine but partly mechanical. Revenue reached a 10-year high of KRW 50.1bn, operating profit turned positive at KRW 2.23bn, and a working-capital release produced record free cash flow of KRW 5.9bn [S2, S3]. The more recent data are less encouraging. LTM revenue had fallen to KRW 47.0bn by June 2026, exports were drying up, and R&D spending had declined for four consecutive years before a marginal LTM uptick [S2, S5].
At KRW 931, the shares trade at about 1.1x book, about 22x trailing earnings, and about 12.5x trailing EV/EBITDA [S2, S3; computed]. These multiples look neither cheap on earnings nor expensive on assets. The net cash position (about 11% of market cap) and land carried well below likely market value provide a floor. The thin, volatile margin structure (9–17% gross, −4% to +7% operating over five years) caps the ceiling [S2].
The incremental positives are capital-allocation signals: a 40% dividend increase, the first treasury-share trust in at least a decade, and steady insider accumulation [S3]. These suggest management is responding to Korea's shareholder-return agenda. The open question is whether the buyback shares are cancelled and whether payouts rise meaningfully from about 18%.
The investment case strengthens materially only if three things happen together: (i) gross margin holds at or above 16% through FY2026, (ii) API or export revenue re-accelerates, and (iii) management commits to cancelling repurchased shares and to a formal payout policy. Absent these, the stock is likely to remain a range-bound, event-driven micro-cap, with episodic spikes tied to LG-related or paclitaxel headlines that fundamentals do not support [S11, S12].
DATA GAPS (NOT PUBLICLY DISCLOSED IN ACCESSIBLE SOURCES)
-
KOSPI listing date; pre-2009 corporate milestones; former-name change date.
-
Auditor identity; board composition (outside directors, committees, chair); executive ages, education, and tenure start dates; individual compensation breakdown.
-
Segment revenue and profit for FY2023–FY2025; segment × geography; country-level revenue; named customers and concentration.
-
Verbatim strategy statements; medium-term targets; guidance.
-
R&D centre details; patent grant chronology.
-
ESG ratings, emissions data, diversity metrics.
-
3-year and 5-year total share-price returns; peer valuation multiples.
-
Terms of any Liporaxel/paclitaxel commercial arrangement; nature of the FY2024 "other operating expense" (KRW 0.98bn) and of the 20 Jul 2026 correction filing.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure | Prior roles / education / age | Source |
|---|---|---|---|---|
Chung Kie-ryun (정기련) | Chief Executive Officer (대표이사); largest shareholder | CEO since at least 2009 (identified as CEO in 2016 and 2018 reporting); start date not publicly disclosed | — | S2, S10, S11 |
Hwangbo Dae-ho (황보대호) | Director; Head of Administration Team | — | Not publicly disclosed; listed as a related party holding 0.17% | S2, S3 |
Kim Byung-cheol (김병철) | Director; Head of Production Team | — | — | S2 |
Statutory auditor and other board members | Not publicly disclosed by name in accessible sources | — | — | — |
“—” = not publicly disclosed.
Workforce Metrics
| Item | FY2025 | Source |
|---|---|---|
Average pay per director/auditor (4 persons) | KRW 120M | S3 (from S1) |
Ratio to average employee pay | 2.0x (employee average KRW 59.75M) | S3 |
Individually disclosed pay (≥ KRW 500M) | None disclosed. Korean law requires individual disclosure only above KRW 500M, which implies no director exceeded that level. | S3 |
Major Shareholders
| Holder | Relationship | Stake (%) | As of | Source |
|---|---|---|---|---|
Chung Kie-ryun | CEO, largest shareholder | 26.16 | FY2025 year-end | S1 |
Hong Young-soon (홍영순) | Related party | 6.71 | FY2025 year-end | S1 |
Ko Hye-ryun (고혜련) | Related party | 0.35 | FY2025 year-end | S1 |
Hwangbo Dae-ho | Related party / director | 0.17 | FY2025 year-end | S1 |
Chung Hyo-i (정효이) | Related party | 0.10 | FY2025 year-end | S1 |
Controlling group total | — | 33.49 | FY2025 year-end | S1 |
Controlling group total (latest) | — | 33.53 | 11 Jun 2026 filing | S3 |
Choi Kyung-ae (최경애) | Other 5%+ holder | 6.31 | Filed 5 Jan 2026 | S3 |
National Pension Service | Institution | 0.20 | End-2024 (down from 0.59% in 2021) | S3 |
Minority shareholders (12,850 holders) | Free float | 57.79 | FY2025 year-end | S1 |
Competitive Landscape
Competitors by Segment
| Segment | Competitor | Type | Relative positioning vs. Bolak |
|---|---|---|---|
Flavours (global) | Givaudan (Switzerland) | Global flavour and fragrance leader; FY2025 sales CHF 7,472M | Vastly larger; full-service creative flavour development; supplies multinational food and beverage companies in Korea [S19] |
Flavours (global) | Symrise (Germany) | Global flavour, fragrance, and nutrition supplier; FY2025 sales EUR 4,929M | Vastly larger; strong in Asia [S20] |
Flavours (global) | IFF (USA) | Global flavours, fragrances, and ingredients | — |
Flavours (global) | dsm-firmenich (Switzerland/Netherlands) | Global flavour, fragrance, and nutrition | — |
Flavours (Japan/Asia) | Takasago International; T. Hasegawa | Japanese flavour houses active in Korea | — |
Natural colours | Oterra; GNT Group | Global natural-colour specialists | — |
Gum base | Global gum-base specialists (e.g., Gum Base Co., Italy) and captive gum-base production at large confectioners | Specialist producers | Bolak competes as a domestic supplier with likely logistics and service advantages (inference) |
Food additives (Korea) | Diversified Korean ingredient groups, e.g., Samyang Corp (sweeteners), Daesang, CJ CheilJedang (bio-ingredients) | Large domestic chaebol ingredient businesses | Much larger; overlap in sweeteners and functional additives only |
Taxane APIs | Samyang Holdings biopharma (plant-cell-culture paclitaxel, "Genexol"); Chinese and Indian taxane API makers | Domestic and Asian API producers | Samyang is the domestic benchmark. It pioneered mass production of paclitaxel by plant-cell culture in 1995 and supplies API to about 30 countries [S13-related DailyPharm coverage]. Bolak uses a natural-extraction route. |
Cellulose ethers (CMC) | Global CMC producers (e.g., Nouryon, Ashland, Daicel) | Large chemical producers | Bolak is a niche pharma- and food-grade supplier |
Peer Comparison FY2025
| Metric | Bolak (FY2025) | Givaudan (FY2025) | Symrise (FY2025) |
|---|---|---|---|
Revenue | KRW 50.1bn | CHF 7,472M | EUR 4,929M |
Organic / like-for-like growth | +5.3% (reported) | +5.1% LFL | +2.8% organic |
Gross margin | 15.6% | 43.5% | — |
EBITDA margin | 7.9% | 23.4% reported (24.2% comparable) | 21.9% (adjusted) |
Net margin | 4.7% | 14.3% | — |
R&D intensity | 1.6% | — | — |
Recent Developments
Bolak issues very few press releases, so the register relies mainly on regulatory filings and market events. Coverage by Korean financial media in the period is sparse.
*Older but still market-relevant: on 8 Oct 2024, shares rose about 21.8% intraday on the reported China NMPA approval of Liporaxel and Bolak's linked paclitaxel delivery-system patent [S12].
*Not identified in the period: guidance revisions, litigation, regulatory sanctions, layoffs, contract-win announcements, or product launches.



